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sought to examine the risk of subsequent ST associated with any DAPT interruption
(aspirin or thienopyridine) with XIENCE V everolimus-eluting coronary stent systems
(EES) (Abbott Vascular, Santa Clara, CA) in 13,259 patients from 7 studies (3 pre-
approval [SPIRIT II, III, IV] and 4 post-marketing [SPIRIT V and SPIRIT Women,
XIENCE V USA, XIENCE V India].
Methods: Definite/probable ST was adjudicated per ARC definition by an independent
clinical events committee. Analyses were conducted to assess overall ST rates and the
relationship between first DAPT interruption and subsequent ST.
Results: 2-year follow-up was complete in 12,552 pts, of whom ST occurred in 93 pts
(0.74%). By Kaplan-Meier analysis the 2-year ST rate was 0.71%. ST rates landmarked
sequentially from 30, 90, 180 and 365 d were 0.34%, 0.06%, 0.07%, 0.14%,
respectively. DAPT interruption data at different time intervals appears in the Table.
Conclusion: In this analysis of 13,259 patients receiving EES in a broad cross-section
of geographies, patients and lesions, 2-year cumulative ST rates were 0.74%. DAPT
interruption before 30 days was strongly associated with increased ST. Conversely, ST
rates were not increased with DAPT discontinuation after 30 days in patients who
received EES.
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Background: There are limited data about differences in outcome after stent
thrombosis (ST) according to the timing of the event.
Methods: A total of 3,602 pts with ST-segment elevation myocardial infarction
(STEMI) treated with primary percutaneous coronary intervention (PCI) were included
in HORIZONS-AMI. Stents were implanted in 3,202 pts. During 3-year follow-up
ARC-defined definite/probable ST occurred in 156 pts (4.9%). We compared 1-year
clinical outcomes after ST according to the timing of the event; acute (<24 hours),
subacute (24 hours-30 days), late (30 days-1 year), and very late (1 year-3 years).
Results: Acute ST occurred in 28 pts (18%), subacute ST in 48 pts (31%), late ST in
30 pts (19%), and very late ST in 50 pts (32%). One year mortality is shown in Figure
1. Subacute ST had the highest 1-year mortality (39.7%) while mortality for other ST
types was <10%. Most deaths occurred within the first weeks after the ST event. Rates
of reinfarction were higher in patients with late (77.1%) and very late ST (86.0%)
compared with acute (57.1%) and subacute ST (59.3%, p for trend <0.01). The
composite endpoint of death/reinfarction occurred with similar frequency in all ST
types (acute 64.3%, subacute, 83.3%, late 80.0%, very late 86.0%, p for trend
0.13).Major bleeding was more frequent in patients with acute (26.8%) and subacute
ST (13.6%) compared with late (3.7%) and very late ST (6.3%, p for trend 0.03).
Conclusion: This large cohort of patients with ST after primary PCI for STEMI
showed that mortality was highest after subacute ST. Reinfarction was less frequent,
and major bleeding was more frequent in patients with acute and subacute ST compared
with late and very late ST.
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Background: The aim of this study is to compare the safety and efficacy of Sirolimus
(SES), Paclitaxel (PES), EPC capture (ECS), Zotarolimus (ZES-R/ Endeavor
Resolute), BiolimusA9 (BES) and Everolimus-eluting stent (EES) on the outcome of
percutaneous coronary intervention in patients with diabetes mellitus (DM).
Methods: A prospective analysis of 2972 patients with DM (808 SES, 720 PES, 299
ECS, 404 ZES-R, 320 BES, 421 EES) in six high volume Asian centers after successful
stenting was performed. The study endpoints were 30 days major adverse cardiac
events (MACE) and 12, 24 and 36 months target lesion revascularization (TLR) and
MACE.
Results: See table for clinical results.
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